Realm Therapeutics Announces Completion of $26 million Private Placement


Realm Therapeutics plc (AIM: RLM) has announced the private placement of $26 million, previously disclosed September 21, was approved by its shareholders at a general meeting in London on October 9.

As quoted in the press release:

The 66,396,485 new ordinary shares issued by the Company in the PIPE were admitted to trading on AIM, a market operated by the London Stock Exchange, on October 10, 2017. US and UK healthcare specialist funds that participated in the PIPE included OrbiMed, BVF Partners LP, RA Capital Management, Abingworth BioEquities Master Fund Ltd and Polar Capital.


Realm Therapeutics plc
+44 (0) 20 3727 1000

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

FTI Consulting
+44 (0) 20 3727 1000

Simon Conway / Mo Noonan

N+1 Singer (Nominated Adviser and Broker)
+44 (0) 20 7496 3000

Aubrey Powell / Lauren Kettle

Click here to read the full press release.

table.inline-text-ad {
border-left: none;
border-right: none;

.inline-text-ad h1 {
font-size: 18px !important;
font-weight: bold !important;

.inline-text-ad p {
font-size: 1.0rem;

“The “Trump Bump” is causing biotech stocks are going up, up and up.”

For a limited time, download the latest biotech report – For FREE – and get everything you need to know on the biotech industry and on biotech investing.

Get My Free Report
Click here to download for free

The post Realm Therapeutics Announces Completion of $26 million Private Placement appeared first on Investing News Network.

Continue Reading

Comments are closed.